Our results show that amplification of targetable oncogenes is frequent in BRCA1/2 mutation negative MBCs and may identify MBC subsets characterized by aggressive phenotype that may benefit from potential targeted therapeutic approaches. This evidence concerns the gene BRCA1 and maternal uniparental disomy of chromosome 20.